What is indigenous medical device manufacturing in India?

It is the domestic production of medical devices (implants, stents, diagnostic equipment, etc.) that are currently 60–70% imported. The Indian government is actively promoting this via tax incentives and procurement preferences to reduce healthcare costs and strengthen the supply chain. Union Minister Jitendra Singh stated in March 2026 that India is shifting from an import-dependent pharma-medical ecosystem to one driven by indigenous capabilities.

How much does it cost to start medical device manufacturing in India?

Approximately ₹3–8 crore for an MVP focusing on 1–2 high-demand device categories. Breakdown: manufacturing setup (₹1.5–3 crore), regulatory certifications/approvals (₹30–60 lakh), initial raw material inventory (₹50 lakh–1 crore), distribution and marketing (₹40–80 lakh). Larger-scale operations with full R&D and backward integration require ₹20–50 crore.

Is medical device manufacturing profitable in India?

Yes. Profit margins on domestic devices are 35–50% (vs. 15–25% on imports due to tariffs/logistics). A ₹5 crore device manufacturing unit can generate ₹1.5–2 crore EBITDA annually. Government contracts (PMJAY hospitals, state tenders) guarantee bulk orders; export to SAARC adds 20–30% upside. Market is growing at 12–15% CAGR with acute shortage of domestic supply.

What regulations apply to medical device manufacturing in India?

CDSCO approval under Medical Devices Rules 2017 (mandatory for all devices); BIS certification (IS 1404 for implants); ISO 13485 QMS certification (mandatory); GST 5% (essential goods category); Import duty on raw materials 7.5–10%; Customs Act 1962 compliance. PMJAY vendor registration required for government hospital sales. State Drugs Controller approval also needed for some device categories.

Medical Devices Manufacturing India 2026 — Guide

AI SummaryIndigenous medical device manufacturing represents a ₹65,000–75,000 crore opportunity in India, driven by the government's push to reduce reliance on imports and make healthcare affordable. As of March 2026, India's pharma ecosystem is rapidly shifting toward domestic production of implants, stents, and diagnostic equipment—categories that historically commanded 60–70% import dependency. MBAs, engineers, and healthcare entrepreneurs with access to ₹3–8 crore capital can launch contract manufacturing or assembly operations targeting hospital procurement networks and PMJAY government tenders. Timing is critical: government incentives (TUF exemptions, PMJAY preferences) are active now, and regulatory pathways (CDSCO approval) are becoming faster; margins on domestic production are 35–50% vs. 15–25% on imports.